EY with Roche Products Ltd

We helped global pharmaceutical company Roche to pilot a completely new approach to outcome-based contracts (OBC), supporting the adoption of value-based healthcare.  

As increasing financial strain looks set to have a detrimental impact on future outcomes for patientsRoche see value-based healthcare as a key response. Also known as outcome-based contracts (OBC), the premise is that healthcare providers only pay for the full amount for treatment if tangible patient outcomes are realised. 

Roche UK partnered with The Christie NHS Foundation Trust, a Cancer Vanguard that treats over 44,000 patients every year, with the aim of launching an OBC pilot in Greater Manchester. Roche asked for EY’s help to create a completely new approach and framework to the design, management and implementation of OBC. The aim was to prove its feasibility and better understand the real-world performance of Roche’s products, and how it can support patients to achieve optimal outcomes during their treatment journey. 

We applied our innovative OBC framework and pioneering Health Outcomes Platform (HOP) to produce a pilot that could be easily replicated, optimised and scaled. Our support enabled Roche and The Christie to carry out an OBC pilot hosted on HOP that measured a range of clinical, economic and humanistic outcomes for over 160 oncology patients. The result was a ‘triple-win’ OBC. 

We helped minimise the administrative burden of data extraction, cleansing and analysis as The Christie could extract raw data and then transfer it to EY for automatic cleansing and analysis. We also overcame the lack of data transparency between The Christie and Roche, where data sensitivity meant that Roche could never have access to raw patient data. As it was hosted on our own HOP solution, both stakeholders had equal visibility of data and therefore could trust the output. 

Following our data infrastructure/need assessment and data action plan, The Christie also has a greater understanding of how its current IT infrastructure can be leveraged to measure patient outcomes. This has helped shape The Christie’s data collection roadmap, prioritising enhancements that allow the company to capture a wider range of outcomes while informing discussions with its data provider vendors. Meanwhile, Roche has gained valuable insight into how its products perform in the real world. The company can use this to inform its supportive care service strategy and improve patient outcomes. 

Overall, the project strongly aligns with EY’s purpose of Building a better working world, by supporting the transition to value-based healthcare which promises better outcomes for patients. We continue to support Roche and the success of the pilot means it can now be used to advocate a wider the shift to value-based healthcare. It has certainly demonstrated that it is possible to overcome the key challenges that previously hindered adoption. 

View the EY profile in the MCA Members Directory.